Split Renal Function Using 99mTc-DTPA Versus 99mTc-DMSA in Kidney Patients of Wide Age Ranges.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-30

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate split renal function using Tc-99m DTPA versus Tc-99m DMSA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR

NCT00470769

Hypertension Renal Failure

UNKNOWN

Early Screening and Diagnosis of CKD

NCT02841371

Kidney; Disease (Functional) Chronic Kidney Disease

RECRUITING

Renal MR Feasibility in Renal Disease

NCT03578523

Renal Disease

UNKNOWN

Kidney Uptake at F-18 FDG PET/CT Studies and Renal Function Status

NCT06268067

Renal Uptake at F-18-FDG PET/CT

NOT_YET_RECRUITING

Role OF Geometric Mean in Estimation OF Differential Renal Function in DMSA Scintigraphy

NCT05344807

Patients Referred for Renal DMSA Scintigraphy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Split renal function (SPR) is a determination of the relative contribution of each of the two kidneys . It gives a useful information in several conditions such as evaluating unilateral renal disorders, assessing individual kidney function before and after intervention, and before live donor nephrectomy. Different radiopharmaceuticals such as technetium-99m dimercaptosuccinic acid (99mTc-DMSA), technetium-99m diethylenetriaminepentaaceticacid (99mTc-DTPA), technetium-99m mercaptoacetyltriglycine (99mTc-MAG3), Iodine 131 orthoiodohippurate and more recently technetium-99 m ethylenedicysteine (99mTc-EC) were used, However, 99mTc-DMSA as a static renal agent is considered the most reliable method to measure relative renal function and the most appropriate tracer for renal cortical imaging . In some papers, it is emphasized that relative renal function calculated with 99mTc-DTPA is as reliable as 99mTc-DMSA .‬ The investigators design the study to evaluate the difference in estimation of split renal function using the available two radiopharmaceuticals: Tc-99m DTPA and Tc-99m DMSA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Difference in Estimation of Split Renal Function Using the Two Radiopharmaceuticals:Tc-99m DTPA & Tc-99m DMSA in Kidney Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renal scintigraphy

5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.

Group Type OTHER

renal scintigraphy

Intervention Type OTHER

99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.

99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

renal scintigraphy

99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.

99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

99mTc-DTPA & 99mTc-DMSA renal scintigraphy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Kidney patients of wide age ranges.
2. Patients with renal disorders who referred for DMSA and DTPA split renal function.
3. Patients able to sleep in a fixed position for 20 minutes.